Related Experiment Videos
Ber-H2 (CD30) immunohistochemical staining in malignant melanoma
1Department of Pathology, Saint Louis University, Missouri, USA.
Summary
CD30 expression is rare in malignant melanoma, contrary to some previous reports. This study found minimal to no Ber-H2 antibody labeling in most melanoma cases, questioning its diagnostic utility for this cancer.
Area of Science:
- Oncology
- Immunohistochemistry
- Dermatopathology
Background:
- Malignant melanoma can be misdiagnosed as CD30-expressing lymphomas or carcinomas.
- CD30 is a diagnostic marker for certain malignancies like Hodgkin's disease.
Purpose of the Study:
- To investigate the frequency of CD30 (Ber-H2) immunoreactivity in malignant melanoma.
- To compare findings with prior studies suggesting frequent CD30 expression in melanoma.
- To discuss the interpretation of Ber-H2 staining in melanoma tissues.
Main Methods:
- Retrospective immunohistochemical study.
- Analysis of archival paraffin-embedded tissue from 24 primary and metastatic melanoma lesions.
- Use of Ber-H2 monoclonal antibody (anti-CD30).
Main Results:
- No significant Ber-H2 labeling was observed in the majority of melanoma cases studied.
- Only one case showed variable, weak cytoplasmic staining.
- Findings contrast with previous reports of frequent CD30 expression in melanoma.
Conclusions:
- CD30 (Ber-H2) expression is infrequent in malignant melanoma.
- The diagnostic utility of Ber-H2 for melanoma requires careful interpretation.
- Further investigation into CD30 IHC staining in formalin-fixed, paraffin-embedded tissues is warranted.